Mode
Text Size
Log in / Sign up
Phase 4 Completed N=27 Treatment

A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration

Source: ClinicalTrials.gov NCT01453374 ↗
Enrolled (actual)
27
Serious AEs
22.2%
Results posted
Jul 2015
Primary outcomePrimary: Incidence of Subject Re-arrest — 6; 2 participants re-arrested — p=>0.05

Summary

This phase 4 study will evaluate the feasibility of initiating subjects on VIVITROL in prison and continuing VIVITROL upon release into the community.

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of Subject Re-arrest
6; 2 >0.05
SECONDARY
Incidence of Subject Re-incarceration
5; 2 >0.05
SECONDARY
Opioid Use
11; 2 <0.05 sig
SECONDARY
Opioid Overdose
1
SECONDARY
Drug Abuse Treatment Program Entry
24
SECONDARY
Retention in the Community
10
SECONDARY
Opioid Craving
21.0; -11.0
SECONDARY
Opioid Dependence
SECONDARY
Cocaine Use
5; 0 <0.10
SECONDARY
Criminal Activity
18

Eligibility Criteria

Inclusion Criteria

  • Not currently addicted to opioids, but has a diagnosis of pre-incarceration opioid dependence
  • Inmate at the Metropolitan Transition Center (Baltimore, MD), Maryland Correctional Institute for Women (Jessup, MD), Baltimore Pre-Release Unit (Baltimore, MD), or Jessup Pre-Release Unit (Jessup, MD) and eligible for release within 30 days of screening
  • Expressing a goal of opiate-free treatment upon release
  • Currently opioid free
  • Planning to live in the Baltimore, MD area for at least 8 months following prison release

Exclusion Criteria

  • Pregnancy and/or breastfeeding
  • Clinically significant active medical condition
  • Active hepatitis
  • Past or present history of an AIDS-indicator disease in subjects who are infected with HIV
  • Any untreated or unstable psychiatric disorder(eg, bipolar with mania)
  • Recent suicidal ideation
  • Current chronic pain diagnosis for which opioids are prescribed
  • Positive drug test for opioids
  • History of drug overdose within the past 3 years requiring inpatient hospitalization
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01453374). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search